Treatment Of Hematologic Malignancies Associated With Circulating Tumor Cells Using Chimeric Anti-Cd20 Antibody

Patent No. EP2055313 (titled "Treatment Of Hematologic Malignancies Associated With Circulating Tumor Cells Using Chimeric Anti-Cd20 Antibody") was filed by Biogen on Nov 9, 1999. The application was issued on Apr 29, 2015.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2055313

BIOGEN
Application Number
EP09002504A
Filing Date
Nov 9, 1999
Status
Revoked
Aug 21, 2020
Publication Date
Apr 29, 2015